Clinical Trials on Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in New Zealand

Total 518 results

National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Kite, A Gilead Company

Terminated

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ZUMA-8)

Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

United States, Italy
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
National Cancer Institute (NCI)

Terminated

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Terminated

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
SecuraBio

Withdrawn

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Hackensack Meridian Health
Celgene Corporation

Terminated

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (VZCLLPI0146)

Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)

United States
Spectrum Pharmaceuticals, Inc

Completed

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
SecuraBio

Completed

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, United Kingdom, Australia, Germany
University of Rochester

Active, not recruiting

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
MingSight Pharmaceuticals, Inc

Recruiting

A Study Of The Selective PKC-β Inhibitor MS- 553

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Aggressive Lymphoma

United States
SecuraBio

Completed

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, Germany, United Kingdom, Australia
GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
AbbVie
Genentech, Inc.

Completed

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Pharmacyclics LLC.

Completed

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Spain, United States, Australia, France, Czechia, Hungary, Poland
AbbVie
Infinity Pharmaceuticals, Inc.

Withdrawn

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma

United States
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR)

Recruiting

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada
Titan Pharmaceuticals

Terminated

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia

Lymphoma, Small Lymphocytic | Leukemia, Lymphocytic, Chronic

United States
Celgene Corporation

Completed

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Germany
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Richter Syndrome and other conditions

United States
Novacea

Unknown

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Chronic Lymphocytic Leukemia | Leukemia, B-cell | Small Lymphocytic Lymphoma | Leukemia, Lymphocytic

United States, Spain, Canada, Korea, Republic of, Taiwan, Australia, Japan, New Zealand, Italy, Czechia, China, Hungary, Israel, Belgium, France, Poland, Germany, Argentina, United Kingdom, Brazil, Turkey, Chile, Austria
AstraZeneca

Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

India
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland
AbbVie

Recruiting

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Australia, China, New Zealand, Taiwan
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Active, not recruiting

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Aptose Biosciences Inc.

Active, not recruiting

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Hangzhou Zenshine Pharmaceuticals Co., Ltd.

Terminated

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Non-hodgkin Lymphoma

United States
SecuraBio

Terminated

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (REAL)

Lymphoma | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia, Belgium
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel, Taiwan, United Kingdom, Chile, Canada, Japan, Brazil, China
Pharmacyclics LLC.

Completed

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Ascenta Therapeutics

Completed

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | Small Lymphocytic Lymphoma

United States
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China

Clinical Trials on Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations